The synthesis of gastric and duodenal mucosal prostaglandin E2, prostaglandin I2, and thromboxane B2 during a 60 minute incubation of biopsy specimens, the degree of endoscopic and histological damage, and the antiinflammatory response were all studied after a four week, double blind study of therapeutic doses of two non-steroidal anti-inflammatory drugs, naproxen and etodolac, received by 27 patients with active rheumatoid arthritis (13 receiving 
It has been increasingly recognised that nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandins have opposite effects on the defensive mechanisms of the gastric mucosa. ' 2 One theory suggests that NSAID induced damage is due to suppression of mucosal prostaglandin synthesis.3' Most knowledge in this field has come from animal work, 3 [5] [6] [7] or from studies of young, healthy, human volunteers given single doses or short term courses of aspirin or indomethacin. 8 9 When patients with rheumatic disorders were studied'0 basal values of the ability of gastroduodenal mucosa to synthesise prostaglandins were not known, and the precise nature of their disease was not adequately described.
Etodolac is a member of a new class of NSAIDs, the pyranocarboxylic acids; it has been reported to be better tolerated by the stomach than naproxen," a propionic acid derivative with established efficacy in arthritis, but both agents were reported to have a comparable anti-arthritic activity.'2 An animal study suggested that the different effect of these two agents on the gastric mucosa might be due to the sparing of gastric prostaglandin synthesis by etodolac. 3 The purpose of this prospective, double blind, single centre study was to assess the effect of four weeks' treatment with therapeutic doses of naproxen or etodolac in patients with active rheumatoid arthritis on gastroduodenal mucosal prostaglandin synthesis, anti-inflammatory activity, and endoscopic and histological changes.
Subjects, materials, and methods

PATIENTS WITH RHEUMATOID ARTHRITIS
The patients studied were 18- (1: 1) of methyloximation agent,'6 left overnight at room temperature, and stored at 4°C until needed for radioimmunoassay. After incubation at 20°C the biopsy specimens were incubated at 37°C to stimulate further prostaglandin synthesis. Prostaglandins were assayed in both incubates separately and their values summated. Prostaglandin I2 and thromboxane A2 were measured as their stable metabolites 6-oxoprostaglandin F ,, and thromboxane B2 respectively.
Intra-assay variations were 14 8% for prostaglandin E2, 11-0% for 6-oxo-prostaglandin F(, and 5 0% for thromboxane B2. Inter-assay variations were 13 5-26% for prostaglandin E2, 13 -0% for 6-oxo-prostaglandin Fl((, and 5-6% for thromboxane B2. Cross reactions of the antisera were as follows: prostaglandin E2 (methyloximation agent) antiserum with prostaglandin El 53%, prostaglandin E3 31%, prostaglandin B2 0-2%, 15-oxo-prostaglandin E2 0-25%.
6-Oxo-prostaglandin Fl,, (methyloximation agent) antiserum with thromboxane B2 0-02%, prostaglandin E2 0 01%, prostaglandin El 0-01%. Thromboxane B2 antiserum with prostaglandin D2 0-02%, 6-oxo-prostaglandin El 0-02%, prostaglandin E2 0-02%. The sensitivity of prostaglandin assays (as defined by the amount distinguishable from zero with 95% confidence limit) was 2 pg in all assays. Other details of prostaglandin cross reactions, the sensitivity of prostaglandin assays, intra-assay and interassay precisions have been described previously. ' Informed consent was obtained from patients, and the study was approved by the local ethical committee.
Results
Twenty seven patients completed the study; 13 (nine women, four men), median age 60 years, were found to have been receiving naproxen, and 14 (10 women, four men), median age 50, etodolac. Three further patients were not entered into the study because their initial endoscopy was abnormal and two other patients dropped out before completing the study owing to protocol violations. In the group receiving naproxen six patients smoked, nine were receiving second line drugs, and 10 had previous exposure to NSAIDs, compared with seven, eight, and 11 patients in the etodolac group respectively. Compliance was good and comparable in both groups (median of 89% of naproxen tablets and 87% of etodolac tablets provided were taken), though patients receiving etodolac used less paracetamol.
PROSTAGLANDIN SYNTHESIS
Baseline values were similar in both groups. When all rheumatoid patients were considered as one group there was no significant change in gastric or duodenal prostaglandin values before Table 4 shows the improvement in the indices of rheumatoid disease activity; all variables improved after treatment but not necessarily to a significant degree, apart from the duration of morning stiffness (p<0001) and the articular index (p<005). The overall results indicate that in this small group of patients naproxen and etodolac had similar anti-inflammatory efficacy.
ENDOSCOPIC AND HISTOLOGICAL CHANGES
The second endoscopy was abnormal in seven patients receiving naproxen (54%) with a median score of 2 (0-4), (interquartile ranges), compared with three patients receiving etodolac (21%) and a score of 0 (0-1) (p<0 05). Lesions developed Gastritis20 does not adequately explain the sparing of prostaglandin by etodolac as inflammation was present in similar numbers of patients who took either agent. The significance of this gastritis is unclear; it was not evident on endoscopic examination and was only shown by histology.
Possibly, agents like etodolac may be selective in their effects on various tissues and different types of prostaglandins. Such an effect was previously described with salicylic acid, which caused preferential reduction in prostaglandin E2 in sheep vesicular tissue, whereas indomethacin suppressed all classes of prostaglandins.
The fact that prostaglandins were not suppressed in patients who developed endoscopic abnormalities due to etodolac may mean that the mucosa recovered its capacity to synthesis prostaglandin before full healing of erosions, though we have not shown that such capacity was lost to begin with, or that mechanisms other than prostaglandin deficiency were involved in causing gastric damage: in theory, these could include increased mucosal permeability,22 interference with active ion transport,23 redistribution of mucosal blood flow,24 capillary stasis,25 or interference with the mucus layer. 26 Little is known about the duodenal mucosal prostaglandin response to the intake of NSAIDs as most studies have concentrated on their effect on the gastric mucosa,3 5 thromboxane A2 on the duodenal mucosa was not clarified by those studies. We found that both gastric and duodenal prostaglandin E2/ thromboxane B2 ratios were higher in patients taking etodolac than in those receiving naproxen. The significance of this is not fully clear but it may explain, at least in part, the greater damaging effects of naproxen, though we could not show a significant correlation between the prostaglandin E2/thromboxane B2 ratio and the endoscopic scores.
In conclusion, after four weeks of regular intake in therapeutic doses, naproxen suppressed gastric prostaglandin E2, duodenal prostaglandin E2 and prostaglandin I2, while etodolac did not. At the same time etodolac caused a lesser degree of endoscopic damage than naproxen; this may be related to their different effects on prostaglandins, though there was no correlation between prostaglandin values and endoscopic scores. If it is assumed that more 
